Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ivabradine Zentiva
- Development stage
- Unknown
- Lead developer
- Zentiva
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ivabradine Zentiva is a generic small molecule medication developed by Zentiva for the treatment of cardiovascular conditions. It contains ivabradine hydrochloride, which acts as a selective and specific inhibitor of the cardiac pacemaker *I*<sub>f</sub> current (the 'funny' channel) in the sinoatrial node. By blocking these channels, the drug reduces the spontaneous diastolic depolarization rate, thereby lowering the heart rate without affecting myocardial contractility or ventricular repolarization. It is indicated for the symptomatic treatment of chronic stable angina pectoris in adults with coronary artery disease and for the treatment of chronic heart failure in patients with systolic dysfunction, specifically those in sinus rhythm with an elevated heart rate.
- Brand names
- Ivabradine Zentiva
- Other names
- ivabradine hydrochloride
02
Targets
HCN4 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4)HCN2 (Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2)
Beyond the preview
Go deeper on Ivabradine Zentiva.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ivabradine Zentiva.